Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

BioPharma Credit PLC

Financial Services GB BPCR

0.948GBX
0.004(0.42%)

Last update at 2026-06-12T07:25:00Z

Day Range

0.940.95
LowHigh

52 Week Range

0.760.97
LowHigh

Fundamentals

  • Previous Close 0.94
  • Market Cap106147.41M
  • Volume115284
  • P/E Ratio0.09
  • Dividend Yield7.49%
  • Revenue TTM157.75M
  • Revenue Per Share TTM0.14
  • Gross Profit TTM 157.75M
  • Diluted EPS TTM0.11

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax 129.89M 122.18M 108.45M 182.31M 84.96M
Minority interest - - - - -
Net income 129.89M 122.18M 108.45M 182.31M 84.96M
Selling general administrative 2.30M 1.97M 1.86M 1.70M 2.86M
Selling and marketing expenses - 0.18M 0.17M 0.20M 0.20M
Gross profit 114.50M 124.46M 110.49M 184.25M 87.97M
Reconciled depreciation - - - - -
Ebit - 244.36M 216.91M - 84.98M
Ebitda 129.89M 122.18M 108.45M 182.31M 84.96M
Depreciation and amortization - -122.18000M -108.45700M - -
Non operating income net other - - - - -
Operating income 129.85M 122.18M 108.45M 182.31M 84.96M
Other operating expenses 10.38M 2.28M 51.23M 1.93M 3.01M
Interest expense - - - - 0.00000M
Tax provision 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Interest income 1.62M 1.49M 4.32M 1.15M 3.13M
Net interest income 1.62M 1.49M 4.32M 1.15M 3.13M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - - 108.45M - -
Total revenue 140.23M 124.46M 159.68M 184.25M 87.97M
Total operating expenses -15.34800M 2.28M 2.04M 1.93M 3.01M
Cost of revenue 25.73M 25.57M 25.24M - -
Total other income expense net 0.04M 122.18M -0.00700M - -
Discontinued operations - - - - -
Net income from continuing ops 129.89M 122.18M 108.45M 182.31M 84.96M
Net income applicable to common shares - - - - 84.96M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 1168.42M 1199.62M 1356.73M 1364.02M 1370.62M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets - -31.79700M 0.09M - -
Total liab 17.56M 17.94M 15.87M 26.56M 6.34M
Total stockholder equity 1150.86M 1181.68M 1340.86M 1337.45M 1363.72M
Deferred long term liab - - - - -
Other current liab 14.43M 16.94M 15.87M 1.95M -6.34200M
Common stock 13.74M 13.74M 13.74M 13.74M 13.74M
Capital stock 13.74M 13.74M 13.74M 13.74M 13.74M
Retained earnings 36.09M 560.81M 720.00M - 742.85M
Other liab - - - - 0.56M
Good will - - - - -
Other assets - 1199.62M 48.85M - 1370.62M
Cash 12.59M 5.62M 86.20M 120.53M 94.71M
Cash and equivalents - - - - -
Total current liabilities 14.43M 17.88M 15.87M - 6.34M
Current deferred revenue - - - - -
Net debt -12.58700M -5.62000M -86.20200M -120.52700M -94.70900M
Short term debt - - - - -
Short long term debt - - - - -
Short long term debt total - - - - -
Other stockholder equity 607.12M 607.12M 607.12M 1323.71M 1349.98M
Property plant equipment - - - - -
Total current assets 66.19M 37.42M 155.37M 140.37M 104.72M
Long term investments 1102.23M 1162.20M 1201.36M 1223.65M 1265.90M
Net tangible assets - - - - 1363.72M
Short term investments - - 48.85M - -
Net receivables 53.60M 31.80M 20.23M 19.84M 10.01M
Long term debt - - - - -
Inventory - - -0.09100M - -
Accounts payable 0.00000M 0.95M 0.00000M - 6.34M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 493.91M - 0.00000M - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - -1162.20000M -1201.36200M -1223.65100M -1265.89800M
Deferred long term asset charges - - - - -
Non current assets total 1102.23M 1162.20M 1201.36M 1223.65M 1265.90M
Capital lease obligations - - - - -
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 77.48M 39.07M -1.65600M 48.19M -94.82100M
Change to liabilities - - - 0.00000M -2.49200M
Total cashflows from investing activities 77.48M 39.07M -1.65600M - -94.82100M
Net borrowings - - - - -
Total cash from financing activities -161.64900M -280.41500M -106.99300M -206.62400M -100.15700M
Change to operating activities - - - - -
Net income 129.89M 122.18M 108.45M 182.31M 84.96M
Change in cash 6.97M -129.43300M 14.53M 25.82M -98.56000M
Begin period cash flow 5.62M 135.05M 120.53M 94.71M 193.27M
End period cash flow 12.59M 5.62M 135.05M 120.53M 94.71M
Total cash from operating activities 91.09M 111.91M 123.18M 184.28M 96.44M
Issuance of capital stock - - - - -
Depreciation - - - - -
Other cashflows from investing activities - - - - -
Dividends paid 110.38M 174.66M 89.77M 156.54M 100.16M
Change to inventory - - - - -
Change to account receivables -21.80300M -11.48000M -0.47900M - -9.80200M
Sale purchase of stock -51.27100M -105.75300M -17.22000M -50.08700M 0.00000M
Other cashflows from financing activities - - -1.65600M 48.19M -94.82100M
Change to netincome - - - - 23.77M
Capital expenditures 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -21.23900M -10.35800M -9.22000M 7.88M -12.29400M
Stock based compensation - - - - -
Other non cash items -17.55300M 0.09M 23.95M -5.91800M 23.77M
Free cash flow 91.09M 111.91M 123.18M 184.28M 96.44M

Peer Comparison

Sector: Financial Services Industry: Asset Management

Company Change (GBX) Price (GBX) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x)
BPCR
BioPharma Credit PLC		 0.004 0.42% 0.95 0.09 - 6.73 0.91 7.95
FP
Fondul Proprietatea S.A. GDR		 - -% 4.20 - - 19.30 38.04
MNTN
Schiehallion Fund Ltd		 0.02 1.15% 2.17 0.05 - 4.35 1.25 5.65
BHMU
BH Macro Limited		 -0.03 0.68% 4.39 0.09 - 39.01 0.71 6.47
TFG
Tetragon Financial Group Ltd		 -0.05 0.41% 12.20 0.02 7.04 1.16 0.31 2.06 6.56

Reports Covered

Stock Research & News

View All

Profile

BioPharma Credit PLC, an investment trust, primarily invests in interest-bearing debt assets. The company debt assets are secured by royalties or other cash flows derived from the sales of approved life sciences products. BioPharma Credit PLC was incorporated in 2016 and is based in Leeds, the United Kingdom.

BioPharma Credit PLC

51 Lime Street, London, United Kingdom, EC3M 7DQ

Key Executives

Name Title Year Born
Mr. Pedro Gonzalez de Cosio Investment Mang. NA
Mr. Pablo Gerardo Legorreta Investment Mang. 1964
Mr. Martin G. Friedman Investment Mang. 1965
Mr. Pedro Gonzalez de Cosio Investment Manager NA
Mr. Pablo Legorreta Investment Manager 1963
Mr. Martin Friedman Investment Manager 1965

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.